An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Inclusion Criteria:

• Patients must have

• entered study LIN-MD 01[NCT00765882] or LIN-MD-31 [NCT00948818] and at minimumcompleted the pre-treatment period or

• completed one of the following studies: MCP-103-004 [NCT00306748], MCP-103-005 [NCT00258193], MCP-103-201 [NCT00402337], MCP-103-202 [NCT00460811]

• Sexually active patients of childbearing potential agree to use birth control

• Females of childbearing potential must have a negative urine pregnancy test prior todosing

• Lactating females must agree not to breastfeed

• Patient must meet protocol criteria for CC or IBS-C

Exclusion Criteria:

• Patient must not use protocol-defined prohibited medicine

• Patient is planning to receive an investigational drug at any time during the study

• Patient has an unresolved AE or a clinically significant finding on a physicalexamination, 12-lead ECG, or clinical laboratory test